The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma

The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma

Multiple myeloma and its precursor plasma cell dyscrasias affect 3% of the elderly population in the US. Proteasome inhibitors are an essential part of several standard drug combinations used to treat this incurable cancer. These drugs interfere with the main pathway of protein degradation and lead...

Full description

Bibliographic Details
Main Authors:	Laure Maneix, Melanie A. Sweeney, Sukyeong Lee, Polina Iakova, Shannon E. Moree, Ergun Sahin, Premal Lulla, Sarvari V. Yellapragada, Francis T. F. Tsai, Andre Catic
Format:	Article
Language:	English
Published:	MDPI AG 2021-02-01
Series:	Cancers
Subjects:	ubiquitin-proteasome system mitoprotease multiple myeloma bortezomib carfilzomib drug resistance
Online Access:	https://www.mdpi.com/2072-6694/13/4/843

Similar Items

Proteasome Inhibitors for the Treatment of Multiple Myeloma
by: Shigeki Ito
Published: (2020-01-01)

New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
by: John H. Chen, et al.
Published: (2017-06-01)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
by: Diego Acosta-Alvear, et al.
Published: (2015-09-01)

Practical Aspects of the Use of Carfilzomib in Multiple Myeloma
by: SV Semochkin, et al.
Published: (2018-12-01)

Proteasome inhibitors: situation and prospects (literature review and own data)
by: A. A. Rukavitsyn, et al.
Published: (2016-10-01)

Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
by: Mariah L. Farrell, et al.
Published: (2018-05-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
by: Sang Wu Lee, et al.
Published: (2021-01-01)

Elucidating Proteasome Catalytic Subunit Composition and Its Role in Proteasome Inhibitor Resistance
by: Carmony, Kimberly C.
Published: (2016)

Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity
by: Carol Chen-Scarabelli, et al.
Published: (2017-07-01)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
by: Mohan M, et al.
Published: (2017-03-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure
by: David S. Pitcher, et al.
Published: (2015-07-01)

Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
by: Eric H. Yang, et al.
Published: (2018-03-01)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
by: Arnold Méndez-Toro, et al.
Published: (2020-09-01)

Expression of E3 Ubiquitin Ligases in Multiple Myeloma Patients after Treatment with the Proteasome Inhibitor Bortezomib
by: James Joseph Driscoll
Published: (2015-01-01)

Proteasome inhibitors in cancer therapy
by: Wioletta Romaniuk, et al.
Published: (2015-12-01)

Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
by: Min Seung Lee, et al.
Published: (2021-02-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
by: Bhutani D, et al.
Published: (2017-07-01)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
by: Liping Liu, et al.
Published: (2016-07-01)

Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib
by: Ayse Tarbin Jannuzzi, et al.
Published: (2020-05-01)

Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects
by: Elia Pancheri, et al.
Published: (2020-09-01)

Proteasome inhibitors: A rational for clinical use in the treatment of multiple myeloma
by: Petković Ivan, et al.
Published: (2016-01-01)

Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
by: Jielin Li, et al.
Published: (2021-05-01)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
by: Noah M. Merin, et al.
Published: (2014-12-01)

Carfilzomib boosted combination therapy for relapsed multiple myeloma
by: Steiner RE, et al.
Published: (2017-02-01)

Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis
by: Marwa Tantawy, et al.
Published: (2021-04-01)

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
by: Xiang Zhou, et al.
Published: (2020-04-01)

Experimental Study on the Mechanism of Reversal of Leukemia Multidrug Resistance by Proteasome Inhibitor Bortezomib
by: Ying-chun LI, et al.
Published: (2010-08-01)

Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells
by: Qian Li, et al.
Published: (2018-05-01)

The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
by: Michael A. Harris, et al.
Published: (2020-05-01)

Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
by: Bojana Borjan, et al.
Published: (2020-01-01)

Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy
by: Marcelle G. Meseeha, et al.
Published: (2015-12-01)

A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents
by: Valeria Calafiore, et al.
Published: (2020-09-01)

Therapeutic advancements in multiple myeloma
by: Alessandro eGozzetti, et al.
Published: (2014-09-01)

Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model
by: Aida Varela-Moreira, et al.
Published: (2020-12-01)

Evaluation of the impact of the proteasome inhibitor on calcium channel expression in cardiomyocytes treated with doxorubicin
by: Korga Agnieszka, et al.
Published: (2018-03-01)